External Experts Agree CaridianBCT, Inc.'s Pathogen Reduction Technology Offers Effective Alternative to Gamma Irradiation for Preventing Transfusion-Associated Graft vs. Host Disease

BRUSSELS--(BUSINESS WIRE)--CaridianBCT, a leading global provider of technology, products and services in the blood banking, transfusion medicine and cell therapy industries, today announced that a panel of medical and scientific experts have endorsed the effectiveness of the Mirasol® Pathogen Reduction Technology (PRT) System for replacing gamma irradiation, the current standard of care for preventing transfusion-related Graft vs. Host Disease (GVHD) in platelet recipients. GVHD is an infrequent but often fatal complication associated with transfusion of cellular blood components in patients with suppressed immune systems.

MORE ON THIS TOPIC